Clonidine and Arginine Growth Hormone Stimulation Test Protocol and Interpretation
Growth hormone stimulation testing with clonidine and arginine should only be performed when auxologic criteria are met (declining height SD score or reduced height velocity inconsistent with familial pattern), IGF-I/IGFBP-3 are low, and bone age is significantly delayed, with interpretation using a diagnostic cutoff of GH peak <10 ng/mL in the United States. 1
Pre-Test Requirements and Patient Selection
When to Perform Testing:
- Proceed with provocation testing when: (1) height decline across percentiles or reduced velocity not explained by familial pattern, (2) low IGF-I and/or IGFBP-3 (particularly <−2 SD), and (3) delayed bone age ≥2.2 SDs 2
- Omit provocation testing in the following scenarios: documented pituitary abnormality on imaging plus auxologic criteria; deficiency of another pituitary hormone; extreme short stature (height <−3 SD) with low IGF-I/IGFBP-3 and delayed bone age; or normal bone age with normal height velocity 1, 2
- Provocation testing should never be the sole diagnostic criterion and must be interpreted alongside auxologic findings, IGF-I, IGFBP-3, and bone age 1
Arginine Stimulation Test Protocol
Dosing:
- Pediatric dose: 0.5 g/kg arginine hydrochloride (5 mL/kg of R-Gene® 10) administered intravenously over 30 minutes 3
- Maximum total dose: 30 g arginine hydrochloride (300 mL) regardless of weight 3
- For patients ≤59 kg, withdraw weight-based dose into a separate container to prevent inadvertent overdose 3
Test Procedure:
- Schedule test in the morning following overnight fast that continues throughout testing 3
- Patient must be at bed rest for at least 30 minutes before infusion begins 3
- Infuse arginine through indwelling needle or soft catheter in antecubital vein over exactly 30 minutes 3
- Blood sampling schedule: Draw at −30,0,30,60,90,120, and 150 minutes 3
- Shortened protocol option: Testing can be terminated at 90 minutes without significantly altering validity, as 95.2% of GH peaks occur within this timeframe 4, 5
Clonidine Stimulation Test Protocol
Dosing:
- Clonidine administered orally (specific dosing per institutional protocol, typically 0.15 mg/m² or 4 mcg/kg, maximum 0.25 mg) 6
- Peak plasma levels attained in 1-3 hours after oral administration 6
Test Procedure:
- Same pre-test preparation as arginine: morning scheduling, overnight fast, bed rest for 30 minutes 3
- Blood sampling schedule: Draw at baseline and 30,60,90, and 120 minutes post-administration 7
- Shortened protocol option: The 120-minute sample can be omitted as it affects final results in only 0.4% of cases; 91.6% of peaks occur at 30,60, or 90 minutes 7
- Monitor blood pressure during and after test due to antihypertensive effects 6
Interpretation of Results
Diagnostic Cutoff Values:
- Standard US cutoff: GH peak <10 ng/mL indicates growth hormone deficiency 1
- Alternative cutoff: Some experts advocate <7 ng/mL when using harmonized immunoassays calibrated to IS 98/574 standard 1
- Peak GH <5 ng/mL in the first test significantly increases probability of a positive second test 8
Test Concordance and Reliability:
- Clonidine demonstrates superior reliability with a false-positive rate of only 3.3% and consistent performance in both prepubertal and pubertal children 9
- Clonidine as initial test is more efficient than glucagon, with significantly lower error rates (46.4% vs 69.6% divergent results between first and confirmatory tests) 10
- The combined clonidine-arginine shortened protocol (90 minutes for clonidine, 60 minutes for arginine) has excellent specificity of 99% with kappa 0.98 4
- Overall test reproducibility is limited, with concordance rates around 56.5% between first and second tests 8
Factors Affecting Test Results
Patient Characteristics:
- BMI and weight: Higher BMI-SDS and weight correlate with lower GH peaks, particularly during clonidine testing 11
- Age: Younger children tend to have lower GH peaks in repeat testing 8
- Pubertal status: Lack of sex steroid priming in prepubertal children affects results, though clonidine performs consistently across pubertal stages 1, 9
Metabolic Parameters:
- Triglyceride levels correlate with GH peak during arginine testing 11
- TSH levels are significantly higher in children with confirmed GHD 11
- IGF-I levels are significantly lower in GHD versus other causes of short stature 11
Confirmatory Testing Requirements
- Two positive tests required: A single subnormal response must be confirmed with a second stimulation test using a different agent 3, 10
- Wait at least one day between tests 3
- Arginine has 32% false-positive rate and 27% false-negative rate when used alone 3
- Some patients respond to one agent but not the other, necessitating use of different stimuli 3
Common Pitfalls and How to Avoid Them
- Do not perform testing without meeting auxologic criteria to prevent overdiagnosis and unnecessary treatment 1, 2
- Ensure proper assay standardization: Use harmonized GH assays calibrated to IS 98/574, 22k rhGH isoform standard 1
- Account for nutritional status: IGF-I levels are influenced by weight gain, adiposity, and feeding patterns 2
- Recognize assay variability: Different immunoassays may yield discrepant results due to varying antibody specificity for GH isoforms 1
- Consider timing of GH peaks: While most peaks occur at typical times (30,60,90 minutes), the timing itself does not predict final diagnostic outcome 7
- Minimize patient stress: Apprehension and distress can affect results, particularly in children 3
Post-Test Management
- Once biochemical GHD is confirmed, obtain MRI of hypothalamic-pituitary region to identify structural abnormalities, predict future hormone deficiencies, and assess permanence of deficiency 2
- Initiate daily subcutaneous recombinant human growth hormone at approximately 0.22-0.30 mg/kg/week 2
- Monitor thyroid function during first year of GH therapy as thyroxine levels may decline 2